Skip to main content
Obizur reconstitution video
For Healthcare Professionals
Instruction video on reconstitution of Obizur
Back to top
Risk Minimisation Materials
Search by company, common medicine name, or title of Risk Minimisation Material
Obizur
Takeda UK Ltd
For Healthcare Professionals
OBIZUR▼[antihaemophilic Factor VIII (recombinant), porcine sequence] HCP Brochure
For Healthcare Professionals
Information On Dose Calculation for OBIZURâ–¼[antihaemophilic Factor VIII (recombinant), porcine sequence]
Obodence
Samsung Bioepis UK Limited
Patient Reminder Card
This reminder card contains important safety information that patients need to be aware of before and during treatment with denosumab (Obodence), which is used to treat osteoporosis and bone loss. A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely (may affect up to 1 in 1,000 people) in patients receiving Prolia for osteoporosis. ONJ can also occur after stopping treatment. It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions patients should take.
Olumiant
Eli Lilly and Company Limited
Olumiant 2 mg and 4 mg Film-Coated Tablets guidance for Healthcare Professionals for Atopic Dermatitis and Alopecia Areata
For Healthcare Professionals
Important Risk Minimization information for healthcare professionals prescribing Olumiant for the treatment of Atopic Dermatitis and Alopecia Areata.
Olumiant 2 mg and 4 mg Film-Coated Tablets guidance for Healthcare Professionals for Rheumatoid Arthritis
For Healthcare Professionals
Important Risk Minimization information for healthcare professionals prescribing Olumiant for the treatment of Rheumatoid Arthritis.
Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card
Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card containing important safety information for patients.
Onpattro
Alnylam UK Ltd
Onpattro (patisiran) Educational Material for Healthcare Professionals
For Healthcare Professionals
Educational Material for Healthcare Professionals to ensure safe use of Onpattro in the home setting.
Onpattro (patisiran) Educational Material for Patients
Educational Material for patients for safe use of Onpattro in the home.
OPDIVO
Bristol Myers Squibb Pharmaceuticals limited
Opdivo (nivolumab) Patient Alert Card
The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab. This card was updated in September 2022 (administrative updates only). Changes to the card include design/editorial updates and addition of the Northern Ireland emc url.
Opdualag
Bristol Myers Squibb Pharmaceuticals limited
Opdualag (nivolumab and relatlimab) Patient Card
This card is part of the marketing authorisation for Opdualag (nivolumab and relatlimab) and contains important safety information that you need to be aware of. Please also ensure that you carry this card with you at all times to inform any healthcare professional treating you (e.g., emergency department personnel) that you are receiving treatment with nivolumab and relatlimab. This Patient Card was last updated in August 2025 (administrative updates only).
Opfolda
Amicus Therapeutics UK Ltd
Pombiliti (Cipaglucosidase Alfa) + Opfolda (Miglustat) Information Pack For Healthcare Professionals
Information Pack For Healthcare Professionals
Opsumit
Janssen-Cilag Ltd (a Johnson & Johnson Company)
Orphacol
THERAVIA
Educational material for health care professionals v2.1
For Healthcare Professionals
Modification related to the MAH's name change
Osenvelt
Celltrion Healthcare UK Limited
Ovesse
Aspen
Pharmacy Checklist (Ovesse 1 mg/g Vaginal Cream)
For Healthcare Professionals
This checklist will efficiently guide your consultation with women asking for Ovesse 1mg/g Vaginal
Cream or asking for help for their vaginal atrophy symptoms. It may also be used as the basis for
an online pharmacy screening algorithm.
The checklist should be used by Pharmacy team members who have read and understood the
Ovesse 1mg/g Vaginal Cream Pharmacy Guide and have access to the Summary of Product
Characteristics and Patient Information Leaflet.
Pharmacy Guide & Checklist (Ovesse 1 mg/g Vaginal Cream)
For Healthcare Professionals
This Pharmacy Guide and Checklist is part of a package of materials created by Aspen Pharmacare
UK Limited to support Pharmacies implement the supply of Ovesse 1mg/g Vaginal Cream. It includes
important information to enable community and online Pharmacies to identify women to whom they
can supply Ovesse and the advice they should share to support the appropriate use of Ovesse.
Some women will need to be referred to their GP to confirm their suitability for supply and this
Pharmacy Guide, incorporating the Pharmacy Checklist, will help identify such cases.
Ovranette
Pfizer Limited
PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Checklist for prescribers
For Healthcare Professionals
PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Checklist for prescribers
PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Patient card
PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Patient card
PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Patient sheet
PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Patient sheet
Ozurdex
AbbVie Ltd
Ozurdex - Patient Guide
For Healthcare Professionals
A patient guide to OZURDEX therapy
Ref: UK-OZU-220475
DOP: Feb 2023
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
